The Ramirez family cannot afford insulin
Maria works retail. Luis drives for a warehouse. Their son Diego needs daily insulin. Their marketplace plan lost enhanced subsidies.
What they get now
Rationing doses, crowdfunding, and ER visits when sugar crashes. Out-of-pocket insulin still spikes between refills.
What they should get
Negotiated insulin at near-cost, automatic coverage under Medicare for All / national drug negotiation, and no medical bankruptcy threat (Blueprint FIX-DRUG-001 and FIX-HC-001).
Why not the fair outcome?
Chain of responsibility
Follow the steps from power to lived harm. Each node names an actor, what they did, and what it caused - with receipts.
- 1CorporationsStep 1 of 6
Insulin list prices and rebate games stay far above manufacturing cost.
Effect: Families pay peer-leading U.S. prices even when the molecule is a century old.
Sources
- 2CongressStep 2 of 6
Drug-price negotiation stays narrow; broader Medicare negotiation bills stall.
Effect: Most commercial insulin stays outside the strongest federal bargaining tools.
Sources
- 3Trump adminStep 3 of 6
Enhanced ACA premium tax credits expire; marketplace premiums jump.
Effect: The Ramirez plan deductible rises and pharmacy benefits get thinner.
Sources
- 4State govStep 4 of 6
Medicaid work-requirement waivers add churn for low-wage workers who miss paperwork.
Effect: Coverage gaps appear exactly when refill day hits.
Sources
- 5PropagandaStep 5 of 6
Ads claim drug negotiation kills innovation and that insulin already is fixed.
Effect: Voters shrug while receipts show rationing and ER debt.
Sources
- 6Budget prioritiesStep 6 of 6
Federal capacity shifts toward enforcement and tax cuts for capital income, not pharmacy access.
Effect: Money that could buy insulin security buys detention beds and rebate theater instead.
Sources
Bottom line
Diego does not lack science. He lacks bargaining power, stable coverage, and a Congress that puts pharmacy prices above pharma talking points.